Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / March / The 60 Percent Diagnostic Gap in ME
Clinical care Research and Innovations Molecular Pathology Omics Microbiology and Immunology Screening and monitoring

The 60 Percent Diagnostic Gap in M/E

What earlier mNGS testing could mean for labs and clinicians

By Jessica Allerton 03/12/2026 Discussion 4 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Top Institutions
  • Top Thought Leaders

Share

Objective:

To explore the challenges in diagnosing meningitis/encephalitis (M/E) and the potential of metagenomic next-generation sequencing (mNGS) to improve diagnostic outcomes, addressing the significant diagnostic gap.

Key Findings:
  • Over 60% of M/E cases remain undiagnosed despite extensive testing, highlighting the need for improved diagnostic methods.
  • Earlier use of mNGS could reduce microbiologic testing by over 60% in infectious cases and by more than 90% in autoimmune encephalitis, demonstrating its efficiency.
  • Time to diagnosis could be shortened by approximately 7 days for infectious cases and 10 days for autoimmune encephalitis, significantly impacting patient management.
Interpretation:

mNGS can significantly streamline the diagnostic process for M/E, particularly in complex cases, by providing rapid and comprehensive pathogen detection, which is crucial for timely treatment.

Limitations:
  • mNGS does not replace initial diagnostic tests and requires careful interpretation, particularly regarding false positives.
  • Contamination control is crucial due to the assay's high sensitivity, necessitating strict laboratory protocols.
Conclusion:

Integrating mNGS earlier in the diagnostic pathway for M/E may enhance patient management, reduce unnecessary testing, and improve antimicrobial stewardship, ultimately leading to better patient outcomes.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Jessica Allerton

Deputy Editor, The Pathologist

More Articles by Jessica Allerton

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Global Referral
Research and Innovations
Global Referral

January 12, 2024

10 min read

How digital pathology is transforming the delivery of remote second opinions

Research Roundup
Research and Innovations
Research Roundup

January 31, 2024

1 min read

From spatial transcriptomics to AI diagnosis, we bring you the latest news in pathology and laboratory medicine

Flexible Solutions With FlexVUE
Research and Innovations
Flexible Solutions With FlexVUE

December 29, 2021

1 min read

Quickly customize your immune panels with Ultivue’s new innovation

Defining the Next Generation of NGS
Research and Innovations
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.